Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,735
archived clinical trials in
Psoriasis

Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
377
mi
from 43215
Anderson, SC
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
377
mi
from 43215
Anderson, SC
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigational Site
525
mi
from 43215
Charleston, SC
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigational Site
525
mi
from 43215
Charleston, SC
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
350
mi
from 43215
Greer, SC
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
350
mi
from 43215
Greer, SC
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
321
mi
from 43215
Goodlettsville, TN
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
321
mi
from 43215
Goodlettsville, TN
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
280
mi
from 43215
Knoxville, TN
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
280
mi
from 43215
Knoxville, TN
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
338
mi
from 43215
Murfreesboro, TN
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
338
mi
from 43215
Murfreesboro, TN
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
339
mi
from 43215
Nashville, TN
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
339
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
928
mi
from 43215
Arlington, TX
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
928
mi
from 43215
Arlington, TX
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigational Site
1065
mi
from 43215
Austin, TX
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigational Site
1065
mi
from 43215
Austin, TX
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative site
914
mi
from 43215
Dallas, TX
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative site
914
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
995
mi
from 43215
Houston, TX
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
995
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis
1139
mi
from 43215
San Antonio, TX
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis
1139
mi
from 43215
San Antonio, TX
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1778
mi
from 43215
Spokane, WA
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1778
mi
from 43215
Spokane, WA
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1817
mi
from 43215
Walla Walla, WA
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1817
mi
from 43215
Walla Walla, WA
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1912
mi
from 43215
Wenatchee, WA
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1912
mi
from 43215
Wenatchee, WA
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1647
mi
from 43215
Tucson, AZ
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1647
mi
from 43215
Tucson, AZ
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1931
mi
from 43215
California City, CA
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1931
mi
from 43215
California City, CA
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
930
mi
from 43215
Fort Myers, FL
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
930
mi
from 43215
Fort Myers, FL
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
626
mi
from 43215
Saint Joseph, MO
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
626
mi
from 43215
Saint Joseph, MO
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
406
mi
from 43215
Saint Louis, MO
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
406
mi
from 43215
Saint Louis, MO
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
421
mi
from 43215
Norfolk, VA
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
421
mi
from 43215
Norfolk, VA
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
697
mi
from 43215
Fort Smith, AR
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
697
mi
from 43215
Fort Smith, AR
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
652
mi
from 43215
Rogers, AR
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
652
mi
from 43215
Rogers, AR
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1960
mi
from 43215
Irvine, CA
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1960
mi
from 43215
Irvine, CA
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
432
mi
from 43215
Atlanta, GA
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
432
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
802
mi
from 43215
Baton Rouge, LA
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
802
mi
from 43215
Baton Rouge, LA
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
795
mi
from 43215
Metairie, LA
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
795
mi
from 43215
Metairie, LA
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
798
mi
from 43215
New Orleans, LA
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
798
mi
from 43215
New Orleans, LA
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
645
mi
from 43215
Quincy, MA
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
645
mi
from 43215
Quincy, MA
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
660
mi
from 43215
Jackson, MS
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
660
mi
from 43215
Jackson, MS
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigator Site
1330
mi
from 43215
Albuquerque, NM
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigator Site
1330
mi
from 43215
Albuquerque, NM
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis
481
mi
from 43215
New York, NY
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis
481
mi
from 43215
New York, NY
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
53
mi
from 43215
Fairborn, OH
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
53
mi
from 43215
Fairborn, OH
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
391
mi
from 43215
Exton, PA
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
391
mi
from 43215
Exton, PA
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis
165
mi
from 43215
Pittsburgh, PA
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis
165
mi
from 43215
Pittsburgh, PA
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1052
mi
from 43215
Pflugerville, TX
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1052
mi
from 43215
Pflugerville, TX
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1514
mi
from 43215
Murray, UT
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1514
mi
from 43215
Murray, UT
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
2000
mi
from 43215
Everett, WA
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
2000
mi
from 43215
Everett, WA
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
2007
mi
from 43215
Seattle, WA
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
2007
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative site
395
mi
from 43215
Madison, WI
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative site
395
mi
from 43215
Madison, WI
Click here to add this to my saved trials
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1496
mi
from 43215
St. John's,
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1496
mi
from 43215
St. John's,
Click here to add this to my saved trials
Efficacy and Safety Study of Orally Administered DS107 in Moderate to Severe Atopic Dermatitis Patients
A Randomised, Double-blind, Placebo-controlled, Phase 2b Study to Assess the Efficacy and Safety of Orally Administered DS107 in Patients With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
DS Biopharma Site
416
mi
from 43215
Philadelphia, PA
Efficacy and Safety Study of Orally Administered DS107 in Moderate to Severe Atopic Dermatitis Patients
A Randomised, Double-blind, Placebo-controlled, Phase 2b Study to Assess the Efficacy and Safety of Orally Administered DS107 in Patients With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
DS Biopharma Site
416
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Efficacy and Safety Study of Orally Administered DS107 in Moderate to Severe Atopic Dermatitis Patients
A Randomised, Double-blind, Placebo-controlled, Phase 2b Study to Assess the Efficacy and Safety of Orally Administered DS107 in Patients With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
DS Biopharma Site
3574
mi
from 43215
Cape Town,
Efficacy and Safety Study of Orally Administered DS107 in Moderate to Severe Atopic Dermatitis Patients
A Randomised, Double-blind, Placebo-controlled, Phase 2b Study to Assess the Efficacy and Safety of Orally Administered DS107 in Patients With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
DS Biopharma Site
3574
mi
from 43215
Cape Town,
Click here to add this to my saved trials
Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis.
A Multicenter, 48-Week, Double-Blind, Placebo-Controlled, Parallel-Group Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Ps0010 702
991
mi
from 43215
Houston, TX
Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis.
A Multicenter, 48-Week, Double-Blind, Placebo-Controlled, Parallel-Group Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Ps0010 702
991
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis.
A Multicenter, 48-Week, Double-Blind, Placebo-Controlled, Parallel-Group Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Ps0011 733
485
mi
from 43215
Wilmington, NC
Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis.
A Multicenter, 48-Week, Double-Blind, Placebo-Controlled, Parallel-Group Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Ps0011 733
485
mi
from 43215
Wilmington, NC
Click here to add this to my saved trials
Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis.
A Multicenter, 48-Week, Double-Blind, Placebo-Controlled, Parallel-Group Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Ps0010 733
911
mi
from 43215
Dallas, TX
Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis.
A Multicenter, 48-Week, Double-Blind, Placebo-Controlled, Parallel-Group Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Ps0010 733
911
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis.
A Multicenter, 48-Week, Double-Blind, Placebo-Controlled, Parallel-Group Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Ps0011 209
mi
from 43215
Edmonton,
Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis.
A Multicenter, 48-Week, Double-Blind, Placebo-Controlled, Parallel-Group Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Ps0011 209
mi
from 43215
Edmonton,
Click here to add this to my saved trials
Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis.
A Multicenter, 48-Week, Double-Blind, Placebo-Controlled, Parallel-Group Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Ps0010 704
569
mi
from 43215
West des Moines, IA
Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis.
A Multicenter, 48-Week, Double-Blind, Placebo-Controlled, Parallel-Group Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Ps0010 704
569
mi
from 43215
West des Moines, IA
Click here to add this to my saved trials
Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis.
A Multicenter, 48-Week, Double-Blind, Placebo-Controlled, Parallel-Group Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Ps0011 708
1983
mi
from 43215
Los Angeles, CA
Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis.
A Multicenter, 48-Week, Double-Blind, Placebo-Controlled, Parallel-Group Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Ps0011 708
1983
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis.
A Multicenter, 48-Week, Double-Blind, Placebo-Controlled, Parallel-Group Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Ps0010 706
327
mi
from 43215
Washington,
Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis.
A Multicenter, 48-Week, Double-Blind, Placebo-Controlled, Parallel-Group Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Ps0010 706
327
mi
from 43215
Washington,
Click here to add this to my saved trials